URGN (STOCKS)
UroGen Pharma Ltd. Ordinary Shares
$48.120000
-0.880000 (-1.80%)
Prev close: $49.000000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Elizabeth Barrett
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,987.88M
- Employees
- 253
- P/E (TTM)
- -24.13
- P/B (TTM)
- -17.76
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $188.73M |
| Benefits Costs and Expenses | $286.84M |
| Cost Of Revenue | $17.28M |
| Costs And Expenses | $286.84M |
| Gross Profit | $171.46M |
| Nonoperating Income/Loss | -$872.00K |
| Operating Expenses | $238.11M |
| Selling, General, and Administrative Expenses | $176.85M |
| Research and Development | $61.26M |
| Operating Income/Loss | -$66.65M |
| Income/Loss From Continuing Operations After Tax | -$97.64M |
| Income/Loss From Continuing Operations Before Tax | -$98.11M |
| Income Tax Expense/Benefit | -$472.00K |
| Net Income/Loss | -$97.64M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$97.64M |
| Net Income/Loss Available To Common Stockholders, Basic | -$97.64M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.97 |
| Basic Average Shares | 98,713,400 |
| Assets | $252.59M |
| Current Assets | $235.43M |
| Cash | $108.00M |
| Inventory | $24.59M |
| Other Current Assets | $102.84M |
| Noncurrent Assets | $17.16M |
| Fixed Assets | $597.00K |
| Other Non-current Assets | $16.57M |
| Liabilities | $384.99M |
| Current Liabilities | $61.92M |
| Accounts Payable | $15.47M |
| Wages | $12.25M |
| Other Current Liabilities | $34.19M |
| Noncurrent Liabilities | $323.07M |
| Long-term Debt | $200.00M |
| Other Non-current Liabilities | $123.07M |
| Equity | -$132.40M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$132.40M |
| Liabilities And Equity | $252.59M |
| Net Cash Flow From Operating Activities | -$158.92M |
| Net Cash Flow From Operating Activities, Continuing | -$158.92M |
| Net Cash Flow From Investing Activities | $40.10M |
| Net Cash Flow From Investing Activities, Continuing | $40.10M |
| Net Cash Flow From Financing Activities | $105.29M |
| Net Cash Flow From Financing Activities, Continuing | $105.29M |
| Net Cash Flow | -$13.53M |
| Net Cash Flow, Continuing | -$13.53M |
| Comprehensive Income/Loss | -$97.64M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$97.64M |
| Other Comprehensive Income/Loss | -$97.64M |
| Other Comprehensive Income/Loss Attributable To Parent | -$8.00K |